The peak concentration of ravuconazole in plasma and the area under the concentration-time curve exhibit good linearity across dosages ranging from 2 to 40 mg/kg. At a dose of 2.5 mg/kg, ravuconazole significantly delays mortality compared with control treatment and shows a considerable therapeutic effect against systemic cryptococcosis^[1].

Ravuconazole significantly lowers CFU counts in the lungs compared to control levels. In a rat model of oral candidiasis, ravuconazole also significantly reduces CFU counts in oral swabs compared to controls, performing better than itraconazole and equally to fluconazole^[3].

Ravuconazole displays a broad spectrum of antifungal activity against various fungi including Candida spp., Trichosporon beigelii, CNeoformans, and A. fumigatus. The MIC90 for these fungi ranges from 0.025 to 0.39 mg/mL. It demonstrates enhanced efficacy against strains of Candida krusei, with MICs from 0.05 to 0.39 mg/mL, and shows effective activity against T. mentagrophytes, T. rubrum, M. gypseum, and M. canis, with MICs from 0.05 to 0.39 mg/mL^[1].

Ravuconazole is two to four times more potent than itraconazole and about 40 times more effective than fluconazole against yeasts. Both ravuconazole and itraconazole inhibit most aspergilli effectively, with cidal action against half of the isolates. They are also active against hyaline Hyphomycetes, dermatophytes, and dematiaceous fungi but inactive against Sporothrix schenckii and zygomycetes^[2].